SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci191315 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Chen Ding und 10 weiteren Autor:innen. Beteiligte Einrichtung: F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Armadillo Domain Proteins, Cytoskeletal Proteins, Retinal Ganglion Cells, Optic Atrophy, Autosomal Dominant. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NEI NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Autosomal dominant optic atrophy (ADOA), the most prevalent hereditary optic neuropathy, leads to retinal ganglion cell (RGC) degeneration and vision loss. ADOA is primarily caused by mutations in the optic atrophy type 1 ( OPA1 ) gene, which encodes a conserved GTPase important for mitochondrial inner membrane dynamics. To date, the disease mechanism remains unclear, and no therapies are available. We generated a mouse model carrying the pathogenic Opa1 R290Q/+ allele that recapitulated key features of human ADOA, including mitochondrial defects, age-related RGC loss, optic nerve degeneration, and reduced RGC functions. We identified sterile alpha and TIR motif containing 1 (SARM1), a neurodegeneration switch, as a key driver of RGC degeneration in these mice. Sarm1 KO nearly completely suppressed all the degeneration phenotypes without reversing mitochondrial fragmentation. Additionally, we show that a portion of SARM1 localized within the mitochondrial intermembrane space. These findings indicated that SARM1 was activated downstream of mitochondrial dysfunction in ADOA, highlighting it as a promising therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts, USA.
- Department of Neurobiology, and.
- Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA.
- Department of Genetics, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
Förderung
- NIGMS NIH HHS
- NEI NIH HHS
- NICHD NIH HHS
- NHLBI NIH HHS
- Molloy Family Research and Innovation Fund at BCH
- NIH
- The Jane Coffin Childs Fund for Medical
- F.M. Kirby Neurobiology Center Innovation Grants at BCH
Zitieren
APA
Ding, C., Ndiaye, P. S., Campbell, S. R., Fry, M. Y., Gong, J., Wienbar, S. R., Gibbs, W., Morquette, P., Chao, L. H., Do, M. T. H., & Schwarz, T. L. (2025). SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy. Journal of Clinical Investigation. https://doi.org/10.1172/jci191315
Vancouver
Ding C, Ndiaye PS, Campbell SR, Fry MY, Gong J, Wienbar SR, et al. SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy. Journal of Clinical Investigation. 2025. doi:10.1172/jci191315
BibTeX
@article{Ding2025,
author = {Ding, Chen and Ndiaye, Papa S and Campbell, Sydney R and Fry, Michelle Y and Gong, Jincheng and Wienbar, Sophia R and Gibbs, Whitney and Morquette, Philippe and Chao, Luke H and Do, Michael Tri H and Schwarz, Thomas L},
title = {SARM1 loss protects retinal ganglion cells in a mouse model of autosomal dominant optic atrophy},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci191315}
}
EUVIMED